

REPLIES TO SGX-ST QUERIES REGARDING PRESS RELEASE

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") refers to its press release dated 23 August 2019 and titled "*Cordlife Extends Geographical Footprint to Bangladesh*" (the "**Press Release**"). The Company has received queries from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") in relation to the Press Release (the "**Queries**") and wishes to respond to the Queries as follows:

Question 1:

We refer to the Company's 23 August 2019 announcement titled "Cordlife Extends Geographical Footprint to Bangladesh". It was disclosed that "(t)his move allows the Group to capture surging demand for quality healthcare in one of the world's next great growth markets due to the rise of a progressive Middle and Affluent Class". Please provide the background and track record of Cordcell and how it can help the Company to "capture surging demand for quality healthcare in one of the world's next great growth markets".

Company's response to Question 1:

Cord Cell Bangladesh Limited ("**Cordcell**") is a private company limited by shares that was incorporated in Dhaka, Bangladesh in 2019. Led by a team of experienced professionals which include a practising obstetrician/gynaecologist and pharmacist, Cordcell is a company focusing on the distribution of healthcare services such as cord blood and cord tissue banking in Bangladesh. Based in Dhaka, the capital and the largest city of Bangladesh, Cordcell, as the appointed marketing agent of Cordlife Sciences (India) Pvt. Ltd. ("**Cordlife India**"), will be well placed to market services of the Group to patients across Bangladesh through private hospitals, obstetricians and gynaecologists.

Question 2:

What is the Company's investment into Bangladesh? Please provide details and quantify where necessary.

Company's response to Question 2:

Cordlife India has entered into a marketing agreement with Cordcell, in relation to the appointment of Cordcell as Cordlife India's marketing agent in Bangladesh. Under the terms of the marketing agreement, Cordcell will generally carry out promotional and marketing activities to raise awareness of the Group's products and services and will also be responsible for the proper discharge of end-to-end operational support to clients in Bangladesh. The Group has not made any investments or acquisitions in Bangladesh in relation to the appointment of Cordcell, and at present, has no plans to make any investments or acquisitions in Bangladesh in relation to the collaboration with Cordcell.

Question 3:

Will this expansion change the risk profile of the Company? Please provide details required under Listing Rule 1010 if applicable. Please also provide basis for the Board of Directors' views.

Company's response to Question 3:

As stated in the response to Question 2 above, the Company's collaboration with Cordcell in Bangladesh is only limited to the appointment of Cordcell as Cordlife India's marketing agent in Bangladesh, in accordance with the marketing agreement entered into between both parties. As the Group has not made any investments or acquisitions in Bangladesh in relation to such collaboration, the Board of Directors is of the view that this collaboration is not expected to change the risk profile of the Company. As this collaboration between Cordlife India and Cordcell would not fall under the definition of a "transaction" for the purposes of Rule 1002(1) of the Listing Manual, the details prescribed under Listing Rule 1010 are accordingly not applicable.

By Order of the Board

CORDLIFE GROUP LIMITED

Ms. Tan Poh Lan

Executive Director and Group CEO

29 August 2019